The Experts below are selected from a list of 10302 Experts worldwide ranked by ideXlab platform
Guanglin Cui - One of the best experts on this subject based on the ideXlab platform.
-
comparison of apolipoprotein b a1 ratio Framingham Risk Score and tc hdl c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention
Lipids in Health and Disease, 2019Co-Authors: Min Tian, Zhilei Shan, Dao Wen Wang, Jiangang Jiang, Guanglin CuiAbstract:Apolipoproteins (Apo) are known atherogenic factors that play important roles in many mechanisms related to coronary heart disease (CHD). However, it is unclear whether the apoB/apoA1 ratio is an equal or a better predictor than the Framingham Risk Score or TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention. We investigated the association between Apolipoprotein B/A1 ratio and cardiovascular Risk factors as well as the severity of CHD in 2256 Han Chinese patients. The potential of Apolipoprotein B/A1 ratio, Framingham Risk Score and TC/HDL-c were assessed as a marker to predict cardiovascular adverse events in a prospective subgroup of 1639 CHD patients during a 5-year follow-up. In the multivariate model, adjusted odds ratios (ORs) were significant for 3-VD vs. 1-VD (OR = 2.36; 95% CI: 1.65–3.38, for the fourth vs. first quartile; Ptrend < 0.001). The subgroup analysis showed that patients with a higher ApoB/ApoA1 ratio had an increased Risk of developing multi-branch lesions and potentially suffer more cardiovascular adverse events (anginas, myocardial infarctions, heart failures, strokes, and cardiac deaths) in the future (adjusted HR =1.92; 95% CI: 1.10–3.13, for the fourth vs. first quartile). In the ROC analysis, the AUC for ApoB/A1 ratio was larger than that of Framingham Risk Score (0.604 vs. 0.543, p = 0.01) and TC/HDL-c (0.604 vs. 0.525, p < 0.01). Our results suggest a significant association between ApoB/ApoA1 ratio and CHD severity and cardiovascular outcomes among patients with existing CHD and ApoB/A1 ratio demonstrated a better predictive accuracy for clinical outcomes compared with Framingham Risk Score and TC/HDL-c.
-
Comparison of Apolipoprotein B/A1 ratio, Framingham Risk Score and TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention.
Lipids in health and disease, 2019Co-Authors: Min Tian, Zhilei Shan, Dao Wen Wang, Jiangang Jiang, Guanglin CuiAbstract:Apolipoproteins (Apo) are known atherogenic factors that play important roles in many mechanisms related to coronary heart disease (CHD). However, it is unclear whether the apoB/apoA1 ratio is an equal or a better predictor than the Framingham Risk Score or TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention. We investigated the association between Apolipoprotein B/A1 ratio and cardiovascular Risk factors as well as the severity of CHD in 2256 Han Chinese patients. The potential of Apolipoprotein B/A1 ratio, Framingham Risk Score and TC/HDL-c were assessed as a marker to predict cardiovascular adverse events in a prospective subgroup of 1639 CHD patients during a 5-year follow-up. In the multivariate model, adjusted odds ratios (ORs) were significant for 3-VD vs. 1-VD (OR = 2.36; 95% CI: 1.65–3.38, for the fourth vs. first quartile; Ptrend
Min Tian - One of the best experts on this subject based on the ideXlab platform.
-
comparison of apolipoprotein b a1 ratio Framingham Risk Score and tc hdl c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention
Lipids in Health and Disease, 2019Co-Authors: Min Tian, Zhilei Shan, Dao Wen Wang, Jiangang Jiang, Guanglin CuiAbstract:Apolipoproteins (Apo) are known atherogenic factors that play important roles in many mechanisms related to coronary heart disease (CHD). However, it is unclear whether the apoB/apoA1 ratio is an equal or a better predictor than the Framingham Risk Score or TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention. We investigated the association between Apolipoprotein B/A1 ratio and cardiovascular Risk factors as well as the severity of CHD in 2256 Han Chinese patients. The potential of Apolipoprotein B/A1 ratio, Framingham Risk Score and TC/HDL-c were assessed as a marker to predict cardiovascular adverse events in a prospective subgroup of 1639 CHD patients during a 5-year follow-up. In the multivariate model, adjusted odds ratios (ORs) were significant for 3-VD vs. 1-VD (OR = 2.36; 95% CI: 1.65–3.38, for the fourth vs. first quartile; Ptrend < 0.001). The subgroup analysis showed that patients with a higher ApoB/ApoA1 ratio had an increased Risk of developing multi-branch lesions and potentially suffer more cardiovascular adverse events (anginas, myocardial infarctions, heart failures, strokes, and cardiac deaths) in the future (adjusted HR =1.92; 95% CI: 1.10–3.13, for the fourth vs. first quartile). In the ROC analysis, the AUC for ApoB/A1 ratio was larger than that of Framingham Risk Score (0.604 vs. 0.543, p = 0.01) and TC/HDL-c (0.604 vs. 0.525, p < 0.01). Our results suggest a significant association between ApoB/ApoA1 ratio and CHD severity and cardiovascular outcomes among patients with existing CHD and ApoB/A1 ratio demonstrated a better predictive accuracy for clinical outcomes compared with Framingham Risk Score and TC/HDL-c.
-
Comparison of Apolipoprotein B/A1 ratio, Framingham Risk Score and TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention.
Lipids in health and disease, 2019Co-Authors: Min Tian, Zhilei Shan, Dao Wen Wang, Jiangang Jiang, Guanglin CuiAbstract:Apolipoproteins (Apo) are known atherogenic factors that play important roles in many mechanisms related to coronary heart disease (CHD). However, it is unclear whether the apoB/apoA1 ratio is an equal or a better predictor than the Framingham Risk Score or TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention. We investigated the association between Apolipoprotein B/A1 ratio and cardiovascular Risk factors as well as the severity of CHD in 2256 Han Chinese patients. The potential of Apolipoprotein B/A1 ratio, Framingham Risk Score and TC/HDL-c were assessed as a marker to predict cardiovascular adverse events in a prospective subgroup of 1639 CHD patients during a 5-year follow-up. In the multivariate model, adjusted odds ratios (ORs) were significant for 3-VD vs. 1-VD (OR = 2.36; 95% CI: 1.65–3.38, for the fourth vs. first quartile; Ptrend
Maria J. Wawer - One of the best experts on this subject based on the ideXlab platform.
-
Higher Framingham Risk Score is Associated with HIV-Associated Dementia in Rural Uganda (I7-3B)
Neurology, 2015Co-Authors: Ned Sacktor, Deanna Saylor, Gertrude Nakigozi, Noeline Nakasujja, Xiangrong Kong, Kevin R. Robertson, Ronald H. Gray, Maria J. WawerAbstract:Objective: To determine the relationship between cardiovascular disease Risk as measured by the Framingham Risk Score and HIV-associated dementia (HAD) in HIV+ adults in rural Uganda. Background: Neurocognitive impairment is a common neurologic complication of HIV infection. Recent studies from western cohorts have suggested that the Framingham Risk Score is associated with neurocognitive impairment in HIV+ populations, but this has not been studied in Sub-Saharan Africa. Design/Methods: 299 ARV-naive HIV+ individuals from Rakai District, Uganda underwent a detailed neurological history, examination, neuropsychological test battery (including tests of verbal learning and memory, motor, psychomotor speed, executive function, and verbal fluency), functional assessments, and determination of CD4 count and plasma viral load. Diagnosis of HAD was determined using Frascati criteria combining clinical, neurological, functional, and neuropsychological test data. Framingham Risk was calculated using the modified equation incorporating body mass index (BMI) in place of lipids. Results: Cohort demographics were as follows: mean age=36 years (SD=9), 50[percnt] male gender (n=151), mean years of education=5 (SD=3), mean CD4 count =314 (SD=156) with 33[percnt] with CD4 count
-
higher Framingham Risk Score is associated with hiv associated dementia in rural uganda i7 3b
Neurology, 2015Co-Authors: Ned Sacktor, Deanna Saylor, Gertrude Nakigozi, Noeline Nakasujja, Xiangrong Kong, Ronald H. Gray, Kevin Robertson, Maria J. WawerAbstract:Objective: To determine the relationship between cardiovascular disease Risk as measured by the Framingham Risk Score and HIV-associated dementia (HAD) in HIV+ adults in rural Uganda. Background: Neurocognitive impairment is a common neurologic complication of HIV infection. Recent studies from western cohorts have suggested that the Framingham Risk Score is associated with neurocognitive impairment in HIV+ populations, but this has not been studied in Sub-Saharan Africa. Design/Methods: 299 ARV-naive HIV+ individuals from Rakai District, Uganda underwent a detailed neurological history, examination, neuropsychological test battery (including tests of verbal learning and memory, motor, psychomotor speed, executive function, and verbal fluency), functional assessments, and determination of CD4 count and plasma viral load. Diagnosis of HAD was determined using Frascati criteria combining clinical, neurological, functional, and neuropsychological test data. Framingham Risk was calculated using the modified equation incorporating body mass index (BMI) in place of lipids. Results: Cohort demographics were as follows: mean age=36 years (SD=9), 50[percnt] male gender (n=151), mean years of education=5 (SD=3), mean CD4 count =314 (SD=156) with 33[percnt] with CD4 count<200. No participants had a history of diabetes, and 4 had a history of hypertension (two treated). 81 participants (27[percnt]) met criteria for HAD. Participants with HAD were significantly older than those without HAD (39 years vs. 34 years, p<0.001). Overall, Framingham Risk was low in this population (mean=2.9[percnt], SD=3.8[percnt]) but was significantly higher in those with HAD than those without HAD (4.1[percnt] vs. 2.4[percnt], p=0.02). Conclusions: Framingham Risk Score, a measure of 10-year cardiovascular disease Risk, was associated with HAD in this HIV+ cohort in rural Uganda. Further studies are warranted to determine if aggressive cardiovascular Risk factor control decreases HAD in this population. Study Supported by:MH099733 Disclosure: Dr. Sacktor has nothing to disclose. Dr. Saylor has nothing to disclose. Dr. Nakigozi has nothing to disclose. Dr. Nakasujja has nothing to disclose. Dr. Kong has nothing to disclose. Dr. Robertson has received personal compensation for activities with Abbott Laboratories, Inc. and GlaxoSmithKline as a consultant. Dr. Gray has nothing to disclose. Dr. Wawer has nothing to disclose.
Jiangang Jiang - One of the best experts on this subject based on the ideXlab platform.
-
comparison of apolipoprotein b a1 ratio Framingham Risk Score and tc hdl c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention
Lipids in Health and Disease, 2019Co-Authors: Min Tian, Zhilei Shan, Dao Wen Wang, Jiangang Jiang, Guanglin CuiAbstract:Apolipoproteins (Apo) are known atherogenic factors that play important roles in many mechanisms related to coronary heart disease (CHD). However, it is unclear whether the apoB/apoA1 ratio is an equal or a better predictor than the Framingham Risk Score or TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention. We investigated the association between Apolipoprotein B/A1 ratio and cardiovascular Risk factors as well as the severity of CHD in 2256 Han Chinese patients. The potential of Apolipoprotein B/A1 ratio, Framingham Risk Score and TC/HDL-c were assessed as a marker to predict cardiovascular adverse events in a prospective subgroup of 1639 CHD patients during a 5-year follow-up. In the multivariate model, adjusted odds ratios (ORs) were significant for 3-VD vs. 1-VD (OR = 2.36; 95% CI: 1.65–3.38, for the fourth vs. first quartile; Ptrend < 0.001). The subgroup analysis showed that patients with a higher ApoB/ApoA1 ratio had an increased Risk of developing multi-branch lesions and potentially suffer more cardiovascular adverse events (anginas, myocardial infarctions, heart failures, strokes, and cardiac deaths) in the future (adjusted HR =1.92; 95% CI: 1.10–3.13, for the fourth vs. first quartile). In the ROC analysis, the AUC for ApoB/A1 ratio was larger than that of Framingham Risk Score (0.604 vs. 0.543, p = 0.01) and TC/HDL-c (0.604 vs. 0.525, p < 0.01). Our results suggest a significant association between ApoB/ApoA1 ratio and CHD severity and cardiovascular outcomes among patients with existing CHD and ApoB/A1 ratio demonstrated a better predictive accuracy for clinical outcomes compared with Framingham Risk Score and TC/HDL-c.
-
Comparison of Apolipoprotein B/A1 ratio, Framingham Risk Score and TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention.
Lipids in health and disease, 2019Co-Authors: Min Tian, Zhilei Shan, Dao Wen Wang, Jiangang Jiang, Guanglin CuiAbstract:Apolipoproteins (Apo) are known atherogenic factors that play important roles in many mechanisms related to coronary heart disease (CHD). However, it is unclear whether the apoB/apoA1 ratio is an equal or a better predictor than the Framingham Risk Score or TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention. We investigated the association between Apolipoprotein B/A1 ratio and cardiovascular Risk factors as well as the severity of CHD in 2256 Han Chinese patients. The potential of Apolipoprotein B/A1 ratio, Framingham Risk Score and TC/HDL-c were assessed as a marker to predict cardiovascular adverse events in a prospective subgroup of 1639 CHD patients during a 5-year follow-up. In the multivariate model, adjusted odds ratios (ORs) were significant for 3-VD vs. 1-VD (OR = 2.36; 95% CI: 1.65–3.38, for the fourth vs. first quartile; Ptrend
Zhilei Shan - One of the best experts on this subject based on the ideXlab platform.
-
comparison of apolipoprotein b a1 ratio Framingham Risk Score and tc hdl c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention
Lipids in Health and Disease, 2019Co-Authors: Min Tian, Zhilei Shan, Dao Wen Wang, Jiangang Jiang, Guanglin CuiAbstract:Apolipoproteins (Apo) are known atherogenic factors that play important roles in many mechanisms related to coronary heart disease (CHD). However, it is unclear whether the apoB/apoA1 ratio is an equal or a better predictor than the Framingham Risk Score or TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention. We investigated the association between Apolipoprotein B/A1 ratio and cardiovascular Risk factors as well as the severity of CHD in 2256 Han Chinese patients. The potential of Apolipoprotein B/A1 ratio, Framingham Risk Score and TC/HDL-c were assessed as a marker to predict cardiovascular adverse events in a prospective subgroup of 1639 CHD patients during a 5-year follow-up. In the multivariate model, adjusted odds ratios (ORs) were significant for 3-VD vs. 1-VD (OR = 2.36; 95% CI: 1.65–3.38, for the fourth vs. first quartile; Ptrend < 0.001). The subgroup analysis showed that patients with a higher ApoB/ApoA1 ratio had an increased Risk of developing multi-branch lesions and potentially suffer more cardiovascular adverse events (anginas, myocardial infarctions, heart failures, strokes, and cardiac deaths) in the future (adjusted HR =1.92; 95% CI: 1.10–3.13, for the fourth vs. first quartile). In the ROC analysis, the AUC for ApoB/A1 ratio was larger than that of Framingham Risk Score (0.604 vs. 0.543, p = 0.01) and TC/HDL-c (0.604 vs. 0.525, p < 0.01). Our results suggest a significant association between ApoB/ApoA1 ratio and CHD severity and cardiovascular outcomes among patients with existing CHD and ApoB/A1 ratio demonstrated a better predictive accuracy for clinical outcomes compared with Framingham Risk Score and TC/HDL-c.
-
Comparison of Apolipoprotein B/A1 ratio, Framingham Risk Score and TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention.
Lipids in health and disease, 2019Co-Authors: Min Tian, Zhilei Shan, Dao Wen Wang, Jiangang Jiang, Guanglin CuiAbstract:Apolipoproteins (Apo) are known atherogenic factors that play important roles in many mechanisms related to coronary heart disease (CHD). However, it is unclear whether the apoB/apoA1 ratio is an equal or a better predictor than the Framingham Risk Score or TC/HDL-c for predicting clinical outcomes in patients undergoing percutaneous coronary intervention. We investigated the association between Apolipoprotein B/A1 ratio and cardiovascular Risk factors as well as the severity of CHD in 2256 Han Chinese patients. The potential of Apolipoprotein B/A1 ratio, Framingham Risk Score and TC/HDL-c were assessed as a marker to predict cardiovascular adverse events in a prospective subgroup of 1639 CHD patients during a 5-year follow-up. In the multivariate model, adjusted odds ratios (ORs) were significant for 3-VD vs. 1-VD (OR = 2.36; 95% CI: 1.65–3.38, for the fourth vs. first quartile; Ptrend
